Close Menu

NEW YORK (GenomeWeb) – ERS Genomics said today that it has licensed its CRISPR-Cas9 genome editing patents to the NMI Natural and Medical Sciences Institute at the University of Tübingen and its affiliate NMI TT Pharmaservices.

Under the terms of the non-exclusive licensing deal, NMI and NMI TT will gain access to the ERS patents in order to use them to expand their own custom cell-based research service offerings. Financial details of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.

University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.

The Wall Street Journal examines billing codes used by uBiome.

In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.